Pacira BioSciences, Inc. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Pacira completed the sale of its iovera cryoanalgesia business to Zimmer Biomet Holdings (NYSE: ZBH) on July 31, 2026. The deal structure includes an upfront payment of $70M (received as $73.6M after adjustments) plus up to $70M in revenue-based milestones through December 31, 2031, with potential additional compensation for spasticity program success. Q2 2026 revenues were $192.4M (+6% YoY), with EXPAREL contributing $147.8M. Full-year guidance adjusted downward to $735–760M (from $745–770M) reflecting iovera divestiture.
Why this rating
Divestiture removes ~$27M annualized iovera revenue (~3.6% of guidance midpoint), offset by $140M upfront + milestone cash and focus sharpening. Moderate impact—real strategic choice but not transformational relative to $757.5M market cap.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.